Grant: Discovery Grants Program - Individual
McMaster University
$30,000.00
The Development of Chemical Tool Technology To Modulate Immune Molecular Recognition
EF 2023-24
Résumé
The recognition and elimination of tumors by the immune system is the foundation of modern tumor immunotherapy, the topic of the 2018 Nobel Prize in medicine. The longterm goal of our chemical immunology research program is to design new tools to elucidate the fundamental mechanisms underlying molecular recognition of tumors by antibodies (Ab) and immune cell receptors (ICR). This draws on my extensive experience in the development of synthetic tools called "dimerizers",(D), that modulate the immune recognition of tumors by forming reversible ternary complexes, (Ab:D:L) on the tumor surface through interactions with tumor ligands (L). Dimerizers form ternary complexes by simultaneously binding the protein ligand, L, on the tumor cell surface and an antibody. The bound antibody then activates immune cells through their ICR to destroy the tumor cell through phagocytosis (engulfment) or cytotoxicity (release of cytotoxic granules). Although the factors that control the strength of immune activation against a target cell are not well understood, it is clear that the immune response depends on the number of bound ternary complexes. Forming Ab:D:L ternary complexes with high affinity to occupy all possible ligands on a target cell is a fundamental molecular recognition problem. A major constraint in dimerizer design is that the in vivo concentrations of Ab, and L are so low (nM to pM) that it is difficult to design D to favor the desired ternary complexes over inactive binary complexes Ab:D and D:L. Ternary complex formation is further limited by the fast clearance of D from the circulation in vivo. We aim to design, synthesize and characterize dimerizers that can effectively enhance molecular recognition of target cells by the immune system, by maximizing the stability and formation of ternary vs. binary complexes on the target cell surface in vivo. This will be accomplished through two short term objectives: (1) We will design "covalent dimerizers" (CD) that irreversibly link to antibodies and "kinetically trap" ternary complexes Ab-CD:L (where the dash denotes a covalent linkage). In the event low concentrations of Ab attenuate maximal ternary complex formation on the target surface, we will develop additional bis-reactive CDs that form a covalent linkage to L in addition to Ab to form irreversible ternary complexes Ab-CD-L. (2) We will develop fluorescence polarization kinetic assays to discover and characterize "binding induced" antibody labelling reactions. The new knowledge and technology generated from the proposed research program will provide essential multidisciplinary training while providing technological platforms for new strategies to target foreign pathogens and cells by the immune system.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2020-06917
Name nom
Rullo, Anthony
Department département
Pathology and Molecular Medicine
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2020
Award amount
30000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Bio-organic chemistry
Research subject en
Chimie organique
Research subject fr
Chimie bio-organique
Application title
The Development of Chemical Tool Technology To Modulate Immune Molecular Recognition
Keyword
antibody affinity labelling technology; antibody bio-conjugation strategies; Antibody labelling kinetics; Immune Protein Assembly; Modulating Protein Binding Equilibria; Modulation of ternary complex formation in immunology; Molecular recognition; Probes to study immune recognition; protein-small molecule interactions; synthetic molecule immune modulation
Application summary
The recognition and elimination of tumors by the immune system is the foundation of modern tumor immunotherapy, the topic of the 2018 Nobel Prize in medicine. The longterm goal of our chemical immunology research program is to design new tools to elucidate the fundamental mechanisms underlying molecular recognition of tumors by antibodies (Ab) and immune cell receptors (ICR). This draws on my extensive experience in the development of synthetic tools called "dimerizers",(D), that modulate the immune recognition of tumors by forming reversible ternary complexes, (Ab:D:L) on the tumor surface through interactions with tumor ligands (L). Dimerizers form ternary complexes by simultaneously binding the protein ligand, L, on the tumor cell surface and an antibody. The bound antibody then activates immune cells through their ICR to destroy the tumor cell through phagocytosis (engulfment) or cytotoxicity (release of cytotoxic granules). Although the factors that control the strength of immune activation against a target cell are not well understood, it is clear that the immune response depends on the number of bound ternary complexes. Forming Ab:D:L ternary complexes with high affinity to occupy all possible ligands on a target cell is a fundamental molecular recognition problem. A major constraint in dimerizer design is that the in vivo concentrations of Ab, and L are so low (nM to pM) that it is difficult to design D to favor the desired ternary complexes over inactive binary complexes Ab:D and D:L. Ternary complex formation is further limited by the fast clearance of D from the circulation in vivo. We aim to design, synthesize and characterize dimerizers that can effectively enhance molecular recognition of target cells by the immune system, by maximizing the stability and formation of ternary vs. binary complexes on the target cell surface in vivo. This will be accomplished through two short term objectives: (1) We will design "covalent dimerizers" (CD) that irreversibly link to antibodies and "kinetically trap" ternary complexes Ab-CD:L (where the dash denotes a covalent linkage). In the event low concentrations of Ab attenuate maximal ternary complex formation on the target surface, we will develop additional bis-reactive CDs that form a covalent linkage to L in addition to Ab to form irreversible ternary complexes Ab-CD-L. (2) We will develop fluorescence polarization kinetic assays to discover and characterize "binding induced" antibody labelling reactions. The new knowledge and technology generated from the proposed research program will provide essential multidisciplinary training while providing technological platforms for new strategies to target foreign pathogens and cells by the immune system.